Surgical Outcome Results From SWOG S1505
- 1 September 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 272 (3), 481-486
- https://doi.org/10.1097/sla.0000000000004155
Abstract
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2). Measured parameters included resection rate, margin positivity, pathologic response, and toxicity. Results: Between 2015 and 2018, 147 patients were randomized. Of these, 44 (30%) were deemed ineligible (43 by central review). Of the 103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7). Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy. The grade 3–5 postoperative complication rate was 16%. Of the 73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy. This study represents the first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA. Conclusions: We have demonstrated: (1) Based on the high percentage of enrolled, but ineligible patients, it is clear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resection without prohibitive perioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficult; (4) Major pathologic response rate of 33% is encouraging.Keywords
This publication has 17 references indexed in Scilit:
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreasBMC Cancer, 2017
- 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary CancersAnnals of Surgical Oncology, 2017
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialThe Lancet, 2017
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic CancerJAMA Surgery, 2016
- Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic CancerAnnals of Surgery, 2014
- Whipple Made Simple For Surgical PathologistsThe American Journal of Surgical Pathology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial DesignAnnals of Surgical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010